Dosage Forms

Articles

The acquisition gives Novovax an annual operating capacity of more that one billion doses of COVID-19 vaccine antigen.

Novavax Acquires Praha Vaccines, Expands Large-Scale Vaccine Manufacturing Capacity

The company announced that it has been issued a task order under a present contract with BARDA to use its contract development and manufacturing capabilities and knowledge to assist in the US government’s efforts to deliver COVID-19 vaccines.

Emergent Issued $628 Million Task Order from BARDA to Assist in US COVID-19 Vaccine Efforts

Merck will use Themis’s vector platform to develop a vaccine to prevent COVID-19.

Merck Acquires Themis, Advances SARS-CoV-2 Vaccine Program

Merck will acquire Themis Bioscience and collaborate with IAVI and Ridgeback Bio on COVID-19 vaccines and therapies.

Merck Announces Acquisition, Collaborations for Developing COVID-19 Vaccines and Therapies

CordenPharma and Moderna extended a strategic manufacturing services agreement for the supply of lipid excipients to be used in Moderna’s vaccine against SARS-CoV-2.

CordenPharma to Manufacture Lipid Excipients for Moderna's Vaccine

Advent manufactured the vaccine doses for the Phase 2/3 clinical trial. 

Advent Delivers Doses of COVID-19 Vaccine Candidate for University of Oxford Clinical Trial

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

The White House looks to bring in credible experts for its Operation Warp Speed initiative to advance therapies and vaccines to combat the coronavirus pandemic. 

FDA Leadership Shifts to Advance COVID-19 Treatments

The company announced that participants have enrolled in a Phase 1/2 clinical trial of its COVID-19 vaccine candidate, NVX‑CoV2373, a prefusion protein made using Novavax’s proprietary nanoparticle technology.

Novavax Announces First Participants in Coronavirus Vaccine Clinical Trial

Funding from the US government could lead to 300 million coronavirus vaccine doses by October 2020.

BARDA Commits $1.2 Billion to AstraZeneca Vaccine Program

CanSinoBIO will license-in Precision NanoSystems' proprietary RNA vaccine platform technology while the latter leads the development of the RNA vaccine formulation.